ライフサイエンスコーパス: drug-metabolizing enzyme

1 ytochrome P450 3A4 (CYP3A4), the major human drug metabolizing enzyme.

2 cytochrome P450 3A4, the major human hepatic drug-metabolizing enzyme.

3 tion of cytochrome P450 3A4, the major human drug-metabolizing enzyme.

4 e the drug metabolism by administration of a drug-metabolizing enzyme.

5 cytochrome P4503A4 (CYP3A4), the major human drug-metabolizing enzyme.

6 Human SULT1A1 is an important phase II drug-metabolizing enzyme.

7 tein cytochrome P450 3A4 (CYP3A4) is a major drug-metabolizing enzyme.

8 -2 (NAT2) gene, which expresses an important drug-metabolizing enzyme.

9 ediated by CYP3A4/5, the major human phase I drug metabolizing enzymes.

10 ls of hepatic multicytochrome P450-dependent drug metabolizing enzymes.

11 against the common anti-TB drugs by inducing drug-metabolizing enzymes.

12 ng with enhanced expression of PPARgamma and drug-metabolizing enzymes.

13 macology of other drugs acted on by atypical drug-metabolizing enzymes.

14 450 cytochromes that form the major class of drug-metabolizing enzymes.

15 g efflux transporters and cytochrome P450 3A drug-metabolizing enzymes.

16 lating the hepatic genes that encode various drug-metabolizing enzymes.

17 gnized as one of the most important phase II drug-metabolizing enzymes.

18 the activation of cytochrome P450-containing drug-metabolizing enzymes.

19 r promotion, and induction of genes encoding drug-metabolizing enzymes.

20 rch developments in the understanding of the drug-metabolizing enzymes.

21 receptors are transcriptional regulators of drug metabolizing enzymes and drug export pumps, but onl

22 d on the simultaneous downregulation of many drug metabolizing enzymes and transporter genes.

23 lity arises from differences in abundance of drug metabolizing enzymes and transporters (DMET) among

24 red the role of cervicovaginal cytokines and drug metabolizing enzymes and transporters (DMETs) to el

25 ment of the potential of compounds to affect drug metabolizing enzymes and transporters and perpetrat

26 EGFR mutations and genetic polymorphisms of drug metabolizing enzymes and transporters impedes effec

27 e discuss the importance of polymorphisms in drug metabolizing enzymes and transporters in anticancer

28 MET, and KRAS mutations and polymorphisms in drug metabolizing enzymes and transporters were evaluate

29 obiotics and regulates expression of several drug metabolizing enzymes and transporters.

30 Cytochrome P450 (CYP) 3A4 is a major human drug-metabolizing enzyme and displays pharmacologically

31 ly considered to be the most important human drug-metabolizing enzyme and is known to catalyze the ox

32 tiretroviral therapy (HAART), antiretroviral drug-metabolizing enzyme and transporter gene polymorphi

33 ter including CCR2 190G>A as well as all the drug-metabolizing enzyme and transporter genotypes.

34 in Mdr1a(-/-) rats, the expression levels of drug-metabolizing enzyme and transporter-related genes w

35 tion by regulating the expression of phase I drug-metabolizing enzymes and ATP-binding cassette (ABC)

36 cific isoforms of cytochrome P450, the major drug-metabolizing enzymes and constituting approximately

37 cogenetics explores how genetic variation in drug-metabolizing enzymes and drug targets modifies resp

38 A variants in additional genes that code for drug-metabolizing enzymes and drug transport proteins wa

39 y regulates the expression of genes encoding drug-metabolizing enzymes and drug transporters to essen

40 Elevated levels of drug-metabolizing enzymes and efflux transporters, resul

41 ocyte hypertrophy, and induced expression of drug-metabolizing enzymes and other liver-specific genes

42 ional factors, such as germline mutations in drug-metabolizing enzymes and other pharmacogenomic alte

43 The transcriptional regulation of drug-metabolizing enzymes and transporters (here collect

44 NR1I3) regulates the expression of multiple drug-metabolizing enzymes and transporters in liver.

45 proteins was undertaken using the Affymetrix drug-metabolizing enzymes and transporters panel.

46 modulating the expression of genes encoding drug-metabolizing enzymes and transporters.

47 and a paramount transcriptional regulator of drug-metabolizing enzymes and transporters.

48 endobiotics by regulating the expression of drug-metabolizing enzymes and transporters.

49 ng triggers the trans-activation of critical drug-metabolizing enzymes and transporters.

50 nvolved in the transcriptional regulation of drug-metabolizing enzymes and transporters.

51 tochrome P450 (CYP3A4, the major human liver drug-metabolizing enzyme) and its role in the degradatio

52 showed that CYP3A4, the dominant human liver drug-metabolizing enzyme, and its rat liver orthologs un

53 predict potential effects of sex steroids on drug-metabolizing enzymes, and their relationship with p

54 idant and antimutagen and to induce phase II drug-metabolizing enzymes (anti-initiation activity); it

55 e activity in animal models by modulation of drug-metabolizing enzymes are sulforaphane, an aliphatic

56 ridine diphosphate glucuronosyltransferases) drug-metabolizing enzymes are the autoantigens of syndro

57 rinduction of multicytochrome P450-dependent drug metabolizing enzymes as well as an overexpression o

58 de (1) increased appreciation of the role of drug-metabolizing enzymes, both in determining the predi

59 n of cytochrome P450 3A4 (CYP3A4), the major drug metabolizing enzyme, by dietary compounds has recen

60 An oral cocktail of probe drugs for major drug-metabolizing enzymes (caffeine, tolbutamide, omepra

61 Induction of intestinal drug metabolizing enzymes can complicate the development

62 concentration which a given concentration of drug-metabolizing enzyme can effectively prevent from en

63 rug interactions caused by the inhibition of drug-metabolizing enzymes can now be predicted and exami

64 selective photoswitchable inhibitors of the drug-metabolizing enzymes carboxylesterases 1 and 2 and

65 Substrates of a major drug-metabolizing enzyme CYP2D6 display increased elimin

66 luence of single nucleotide polymorphisms in drug metabolizing enzymes CYP3A4, CYP3A5, and UGT1A4, an

67 The drug-metabolizing enzyme CYP3A4 is often implicated in t

68 efflux transporter P-glycoprotein (P-gp) and drug metabolizing enzyme cytochrome P450 3A4 (CYP3A4) is

69 The drug metabolizing enzyme cytochrome P450 3A4 (CYP3A4) is

70 and binding and allostery in the major human drug-metabolizing enzyme cytochrome P450 3A4 (CYP3A4) we

71 The activities of two other major drug-metabolizing enzymes (cytochrome P450 3A4 and 2D6 [

72 of genetic variation, including variation at drug metabolizing enzyme (DME) loci and drug targets, in

73 drug interactions (DDIs) due to induction of drug metabolizing enzymes (DMEs).

74 C), particularly involving genes that encode drug metabolizing enzymes (DMEs).

75 -including SLC and ABC "drug" transporters, "drug" metabolizing enzymes (DMEs), and regulatory genes-

76 Differential expression of various drug-metabolizing enzymes (DMEs) in the human liver may

77 merging examples of genetic polymorphisms of drug-metabolizing enzymes, DNA repair genes and drug tar

78 spite established effects of sex steroids on drug-metabolizing enzyme expression and activity in vitr

79 cytochrome P450 3A4 (CYP3A4), a major human drug-metabolizing enzyme, further limiting their use in

80 tocol for detecting key polymorphisms in the drug-metabolizing enzyme gene CYP2D6 and a number of lin

81 nd urea synthesis, as well as phase I and II drug-metabolizing enzyme gene expression and activity of

82 A principal advance in the production of drug-metabolizing enzymes has been the development of ca

83 Drug metabolizing enzymes have been studied for decades,

84 P-glycoprotein (P-gp) and the drug metabolizing enzymes have major pharmacokinetic eff

85 The drug-metabolizing enzyme human carboxylesterase 1 (hCE1)

86 ates the expression of drug transporters and drug metabolizing enzymes in a proposed Remote Sensing a

87 and regulatory networks for CYP3A4, the main drug metabolizing enzymes in liver.

88 trans-Stilbene oxide (TSO) induces drug metabolizing enzymes in rat and mouse liver.

89 The role of cytochrome P450 drug metabolizing enzymes in the efficacy of tamoxifen t

90 macological relevance, and AOX3 is the major drug-metabolizing enzyme in rodents.

91 vel epigenetic miRNA regulators of the UGT2B drug-metabolizing enzymes in healthy human liver samples

92 protective cytokines, and did not hamper the drug-metabolizing enzymes in hosts.

93 the CYP3A enzymes, the most abundant phase I drug-metabolizing enzymes in human liver and intestine,

94 l activation of many genes encoding phase II drug-metabolizing enzymes in response to oxidative stres

95 Cytochromes P450 3A4 and 3A5, the dominant drug-metabolizing enzymes in the human liver, share >85%

96 cytochrome P450 3A (CYP3A) members are major drug-metabolizing enzymes in the liver.

97 athway has been identified as a regulator of drug-metabolizing enzymes in the rodent liver.

98 re and the varied expression and activity of drug-metabolizing enzymes in their tissues may affect dr

99 Genotypes in drug-metabolizing enzymes, including functional polymorp

100 re the most versatile and important class of drug-metabolizing enzymes, involved in the metabolism of

101 Understanding of drug-metabolizing enzymes is key to the science of pharm

102 CYP3A4, the dominant human liver drug-metabolizing enzyme, is degraded via a ubiquitin (U

103 Cytochrome P450 2D6 (CYP2D6), a major drug-metabolizing enzyme, is responsible for metabolism

104 Cytochrome P4503A4 (CYP3A4), a major human drug-metabolizing enzyme, is responsible for the oxidati

105 Human NAT2 is characteristic of drug-metabolizing enzymes: it is found in liver and inte

106 Thus, in addition to the phase I drug-metabolizing enzymes known to be decreased during t

107 ATP-binding cassette (ABC) transporters and drug-metabolizing enzymes, many of which are also involv

108 the context of the earlier hypothesis that 'drug-metabolizing' enzymes might modulate the processes

109 al to significantly modulate the activity of drug-metabolizing enzymes (notably cytochrome p450 isozy

110 Cytochrome P450 3A4 is a drug-metabolizing enzyme of extraordinarily broad substr

111 es 210-216 of cytochrome P450 3A4, the major drug-metabolizing enzyme of human liver.

112 rane-bound oxidative partners, including the drug-metabolizing enzymes of the cytochrome P450s (P450)

113 n characterizing the effects of variation in drug metabolizing enzymes on pharmacokinetics.

114 The general insights into the effects of a drug-metabolizing enzyme on drug kinetics in human shoul

115 they are less likely to interact with common drug metabolizing enzymes or transporter proteins.

116 blood levels, and the individual's specific drug-metabolizing enzyme profile may contribute to this

117 Mammalian cytochrome P450 drug-metabolizing enzymes rarely cleave carbon-carbon (C

118 man pregnane X receptor (hPXR) to upregulate drug-metabolizing enzymes, resulting in decreased drug e

119 oval, sponsor, target, chemical class, major drug-metabolizing enzyme(s), route of administration/eli

120 CYP3A, the most important family of drug-metabolizing enzymes, shares many substrates with t

121 The four drug-metabolizing enzymes studied (GST A1-1 and the CYP

122 Genetic variation in drug metabolizing enzymes such as cytochrome P450 2D6 (C

123 of CYP3A4, P-glycoprotein (P-gp), and other drug metabolizing enzymes such as dihydropyrimidine dehy

124 t transcriptionally regulates genes encoding drug-metabolizing enzymes such as CYP3A4, which was prev

125 and xenobiotics, leading to the induction of drug-metabolizing enzymes, such as cytochrome P450.

126 Phase II drug-metabolizing enzymes, such as glutathione S-transfe

127 i-tumor immune response, or delivering a pro-drug metabolizing enzyme that will render the tumor sens

128 Arylamine N-acetyltransferase 1 (NAT1) is a drug-metabolizing enzyme that influences cancer cell pro

129 CYP2C19 is an important human drug-metabolizing enzyme that metabolizes a number of cl

130 uman cytochrome P450 3A4 (CYP3A4) is a major drug-metabolizing enzyme that shows extreme substrate pr

131 re the most versatile and important class of drug-metabolizing enzymes that are induced in mammalian

132 and inflammation affect drug metabolism and drug-metabolizing enzymes, the effect of the acute-phase

133 nzyme are likely to underlie the capacity of drug-metabolizing enzymes to metabolize structurally div

134 tic studies have shown that polymorphisms of drug metabolizing enzymes, transporters and receptors co

135 ociated with polymorphisms in genes encoding drug-metabolizing enzymes, transporters, or drug targets

136 Genetic polymorphisms in drug-metabolizing enzymes, transporters, receptors, and

137 bition/induction studies against major human drug metabolizing enzymes/transporters suggest a low pot

138 l activation of many genes encoding phase II drug-metabolizing enzymes via the antioxidant response e

139 o the second most important class of phase-1 drug-metabolizing enzymes, was immobilized in its active

140 f genetic polymorphisms in each of the three drug-metabolizing enzymes, which impacts on the therapeu

141 (GSTs) comprise a diverse family of phase II drug metabolizing enzymes whose shared function is the c

142 Cytochrome P450 3A4 (CYP3A4) is an important drug-metabolizing enzyme whose substrate binding mechani